bexobrutideg

Small molecule

Also known as RG7473

Phase 3underway

Evidence outlook · registrational

Relapsed/Refractory Chronic Lymphocytic Leukemia: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-10.

Also in development:Chronic Lymphocytic Leukemia · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2 (1)
Chronic Lymphocytic Leukemia
NCT07221500 · Nurix Therapeutics, Inc.
2025-10-15 – 2030-10 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
Phase 1/2 (1)
Chronic Lymphocytic Leukemia
NCT07520006 · Nurix Therapeutics, Inc.
2026-09-30 – 2033-05 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 1 (4)
Chronic Lymphocytic Leukemia
NCT05131022 · Nurix Therapeutics, Inc.
2022-04-13 – 2028-01 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
What this study did
Other / comorbidity
NCT06717269 · Nurix Therapeutics, Inc.
2024-11-30 – 2026-05-01 · Healthy Volunteer
What this study did
NCT06691828 · Nurix Therapeutics, Inc.
2024-11-01 – 2024-12-05 · Healthy Volunteer
What this study did
NCT06593457 · Nurix Therapeutics, Inc.
2024-08-20 – 2024-11-14 · Healthy Volunteers
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Chronic Lymphocytic Leukemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bexobrutideg: this drugPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Remibrutinib
Approved(overall)
Small moleculeBruton's tyrosine kinase (BTK)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Tolebrutinib
Phase 3(overall)
Small moleculeBruton's tyrosine kinase (BTK)
Reliable signal(overall)
No reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Corubrutinib
Phase 2(overall)
Small moleculeBruton's tyrosine kinase (BTK)
Partial signal(overall)
No reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow bexobrutideg to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-01 · NCT05131022 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-01 · NCT07221500 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 3Relapsed/Refractory Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
2033 (1)
May 2033 (1)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch

See the full readout calendar ↗